Genomics

EHE Health is now offering GRAIL's Galleri test, a move that signals a major shift in corporate wellness but raises key questions about cost and access.

An award-winning platform is bringing scientific scrutiny to the supplement aisle. Can this push for transparency force a new standard of accountability?

Parse Biosciences, QIAGEN's strategic acquisition, just partnered with Australia's Garvan Institute. It's more than science—it's a calculated play to win.

Bruker's acquisition of the DISQVER® platform signals a major shift in infection diagnostics, promising to identify thousands of pathogens in hours, not days.

A German court ruling against genomics giant Illumina is more than a legal win for a rival; it's a shockwave hitting the core of biotech innovation and biosecurity.

A new $4,000-a-year service combines genomics and AI for proactive health. But as SONATA launches, it exposes the deep divide in our digital future.

A new deal between genomics giant Illumina and startup Bifrost Biosystems isn't just a business transaction. It’s a strategic play to rewire the very process of drug discovery.

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

AstraZeneca's new deal with genomics firm Helix isn't just a partnership; it's a bet on a future where drug discovery is driven by massive data vaults.

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

Bionano Genomics brings back OGM pioneer Dr. Alex Hastie as CSO. It's a strategic move to accelerate clinical adoption and restore investor confidence.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

With Hillary Aiken leading its new philanthropic arm, 23andMe Research Institute bets on private giving to accelerate its 'public good' DNA revolution.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.